Manali Kamdar, MD, on Bringing Liso-Cel to Earlier Lines of Treatment

Commentary
Video

The associate professor of medicine at University of Colorado discussed data in the primary relapsed LBCL setting.

“Investigating liso-cel even earlier, besides just waiting for the patients to relapse, and then give it to them makes a lot of sense. But I feel it absolutely needs to be tested with scientific rigor within a clinical trial setting. There is some data that's emerging where we could bring liso-cel if interim PET scans are partial response or stable disease. And I think that may be the next opportunity to showcase the strength of liso-cel in terms of bringing it to earlier line settings.”

Lisocabtagene maraleucel (liso-cel) has continued to demonstrate deep responses in patients with primary refractory/relapsed (r/r) large B-cell lymphoma (LBCL) and superiority over standard of care. The therapy is approved under the name Breyanzi for patients with r/r LBCL based off of data from the phase 3 TRANSFORM (NCT03575351) and TRANSCEND trials (NCT02631044).

Updated, 3-year data from TRANSFORM were presented by Manali Kamdar, MD, associate professor of medicine – hematology, University of Colorado School of Medicine - Anschutz Medical Campus, and UCHealth Blood Disorders and Cell Therapies Center at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31 to June 4, in Chicago, Illinois. CGTLive® spoke with Kamdar to learn more about moving liso-cel and other chimeric antigen receptor (CAR) T-cell therapies to earlier lines of therapy.

Click here to view more coverage from the 2024 ASCO meeting.

REFERENCE
Kamdar MK, Solomon SR, Arnason J, et al. Lisocabtagenemaraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. Presented at: 2024 (ASCO) Annual Meeting; May 31 - June 4; Chicago, Illinois. Abstract #7013
Recent Videos
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
© 2024 MJH Life Sciences

All rights reserved.